Aug 13, 2020
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
May 14, 2020
Nobel Laureate, Dr. Ferid Murad, joins HumanN
May 14, 2020
Nitric Oxide Topical Serum Pilot Study for Aging Skin Published in Annals of Plastic and Reconstructive Surgery
Apr 28, 2020
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
Apr 17, 2020
REPEAT: MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
Apr 16, 2020
MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
Apr 07, 2020
Inhalation Anesthesia Market to Garner $1.54 Bn, Globally, by 2026 at 4.2% CAGR, Says Allied Market Research
Mar 24, 2020
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Feb 13, 2020
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
Feb 11, 2020
VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
Jan 24, 2020
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
Dec 12, 2019
Dr. Nathan S. Bryan is the First to Speak at the 27th Annual World Congress About Nitric Oxide's Link to Mental Illness
Dec 11, 2019
Visiongain Publishes Global Inhalation Anaesthesia Market 2019-2029 Report
Dec 10, 2019
Inhalation Anesthesia Market to Witness Significant Growth Due to Rising Number of Emergency Cases & Accidents | Million Insights
Nov 25, 2019
Ketamine Clinics Los Angeles Featured on Emmy® Award-Winning Talk Show The Doctors
Nov 14, 2019
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
Nov 07, 2019
Ketamine Holds Promise in Derailing Veteran Suicide
Nov 07, 2019
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
Oct 28, 2019
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
Oct 14, 2019
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15